Hester Biosciences Limited

HESTERBIO

INE782E01017

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:51 24/05/2024 pm IST			5-day change	1st Jan Change
1,786 ^INR	+0.60%		+2.02%	+22.41%

10/05	Transcript : Hester Biosciences Limited, Q4 2024 Earnings Call, May 10, 2024
10/05	Hester Biosciences' Consolidated Net Profit Rises in Fiscal Q4; Shares Jump 4%	MT

Hester Biosciences Limited Announces Resignation of Jigar Shah as Chief Financial Officer, Effective August 31, 2019

July 26, 2019 at 11:55 am IST

Hester Biosciences Limited announced that Mr. Jigar Shah has submitted his resignation from the post of Chief Financial Officer (Key Managerial Personnel) of the Company. His last day at work would be 31 August 2019.

Latest news about Hester Biosciences Limited

Transcript : Hester Biosciences Limited, Q4 2024 Earnings Call, May 10, 2024	10/05
Hester Biosciences' Consolidated Net Profit Rises in Fiscal Q4; Shares Jump 4%	10/05	MT
Hester Biosciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	10/05	CI
Hester Biosciences Limited Proposes Dividend for the Financial Year 2023- 24	10/05	CI
Hester Biosciences Names COO	29/02	MT
Hester Biosciences Limited Announces Executive Changes	29/02	CI
Hester Biosciences Sees Sharp Decline in Fiscal Q3 Consolidated Profit	02/02	MT
Transcript : Hester Biosciences Limited, Q3 2024 Earnings Call, Feb 02, 2024	02/02
Hester Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02/02	CI
CARE Ratings Keeps BBB+ Rating on Hester Biosciences' Bank Financing; Outlook Stable	03/01	MT
Transcript : Hester Biosciences Limited, Q2 2024 Earnings Call, Nov 07, 2023	07/11
Hester Biosciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	07/11	CI
Hester Biosciences Limited Recommends Dividend for the Financial Year 2022-23, Dividend Payment Date on or After Monday, 25 September 2023	23/23/23	CI
Transcript : Hester Biosciences Limited, Q1 2024 Earnings Call, Aug 08, 2023	08/23/08
Hester Biosciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	08/23/08	CI
Hester Biosciences Limited Announces Board Appointments	27/23/27	CI
Transcript : Hester Biosciences Limited, Q4 2023 Earnings Call, May 17, 2023	17/23/17
Hester Biosciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	17/23/17	CI
Hester Biosciences Limited Recommends Dividend for the Financial Year 2022-23	17/23/17	CI
Hester Biosciences Limited Announces Resignation of Directors	27/23/27	CI
Hester Biosciences Limited Reports Earnings Results for the Nine Months Ended December 31, 2022	31/23/31	CI
Transcript : Hester Biosciences Limited, Q3 2023 Earnings Call, Jan 31, 2023	31/23/31
Hester Biosciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	31/23/31	CI
Hester Biosciences Limited completed the acquisition of 22.5% stake in Thrishool Exim Limited.	31/22/31	CI
Hester Biosciences Acquires Indigenous Technology for Avian Influenza Vaccine	28/22/28	MT

Chart Hester Biosciences Limited

Duration

Period

More charts

Company Profile

Hester Biosciences Limited is an India-based animal healthcare company. The Company is engaged in providing vaccines, health products and diagnostic laboratory services. The Company operates through four segments: Poultry Healthcare, Animal Healthcare, Petcare, and Others. The Animal Healthcare vaccines include Goat Pox Vaccine, Live Brucella, PPR Vaccine - Nigerian 75/1, and PPR Vaccine - Sungri/96. Its Poultry Healthcare products include Gumboro I, Gumboro I +, Inactivated Chick ND, Inactivated Coryza, Inactivated Coryza+, Inactivated EDS, Inactivated FC3, Inactivated FC4, Inactivated IB, Inactivated IB+, Inactivated IB-H52, Inactivated IBD, Inactivated IBD ND, Inactivated IBD ND EDS, Inactivated ND IB, Inactivated Pullet ND, Live B1, Live B1 M48, Live FP, Live H120, Live Las, Live Las Mas, Live M48, Live R2B, Live S-One, MD-Bivalent HVT+SB1, MD-HVT (FD), and Thermostable ND. Its Petcare products include Cefshot Tazo Injection, Hestacef CV, Hestacef DS, Hestaflam Tablet and Hestaliv.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Veterinary Drugs

	1st Jan change	Capi.
HESTER BIOSCIENCES LIMITED	+22.41%	18Cr
ZOETIS INC.	-13.83%	7.76TCr
ELANCO ANIMAL HEALTH INCORPORATED	+12.68%	829.73Cr
BLUESTAR ADISSEO COMPANY	+24.00%	367.35Cr
VIRBAC	+0.14%	327.05Cr
VIMIAN GROUP AB	+14.70%	166.58Cr
JINYU BIO-TECHNOLOGY CO., LTD.	-4.46%	158.72Cr
VETOQUINOL SA	+2.54%	134.85Cr
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-22.01%	130.42Cr
WUHAN KEQIAN BIOLOGY CO.,LTD	-12.12%	114.92Cr

Veterinary Drugs